Seven nodes which strongly linked gene modules (bottleneck hubs) were identified as possible therapeutic targets which include IL6, AKT1, TP53, TNF, JUN, VEGFA, and PPARG. Elevated levels of IL6 have been previously documented in patients with NAFLD [139] and AD [140]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.